CD44 thus provides an attractive target for cancer treatment2–4, and radiolabeled anti-CD44 antibodies (Abs) are being investigated for targeted imaging5–9, as well as radio-immunotherapy of solid tumors10,11. This evidence concerns the gene CD44 and cancer.